<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11263437</article-id><article-id pub-id-type="pmc">2363763</article-id><article-id pub-id-type="pii">6691624</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1624</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Blackhall</surname><given-names>F H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ranson</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Radford</surname><given-names>J A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hancock</surname><given-names>B W</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Soukop</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>McGown</surname><given-names>A T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Robbins</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Halbert</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib></contrib-group><aff id="aff1"><label>1</label>CRC Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester</aff><aff id="aff2"><label>2</label>YCRC Department of Clinical Oncology, Weston Park Hospital NHS Trust, Whitham Road, Sheffield</aff><aff id="aff3"><label>3</label>Department of Medical Oncology, Royal Infirmary, 84 Castle Street, Glasgow</aff><aff id="aff4"><label>4</label>CRC Drug Development Group, Paterson Institute for Cancer Research, Wilmslow Road, Withington, Manchester</aff><aff id="aff5"><label>5</label>Drug Development Office, Cancer Research Campaign, 10 Cambridge Terrace, London</aff><aff id="aff6"><label>6</label>CRC Formulation Unit, Department of Pharmaceutical Sciences, University of Strathclyde, Royal College Building, 204 George Street, Glasgow, UK</aff><pub-date pub-type="ppub"><month>02</month><year>2001</year></pub-date><volume>84</volume><issue>4</issue><fpage>465</fpage><lpage>469</lpage><history><date date-type="received"><day>29</day><month>06</month><year>2000</year></date><date date-type="rev-recd"><day>25</day><month>10</month><year>2000</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2000</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive non-Hodgkin's lymphoma of indolent type (NHL), previously treated with chemotherapy, received a median of 6 (range 1&#x02013;9) intravenous infusions of 25&#x02008;&#x003bc;g/m<sup>2</sup>bryostatin 1 given once weekly over 24 hours. In 14 evaluable patients no responses were seen. Stable disease was attained in one patient for 9 months. The principal toxicities were myalgia and phlebitis. Treatment was discontinued early because of toxicity alone (phlebitis) in 2 patients, toxicity in addition to progressive disease in 3 patients (myalgia and phlebitis <italic>n</italic> = 2; thrombocytopenia <italic>n</italic> = 1) and progressive disease in 5 patients. The results fail to demonstrate efficacy of this regimen of bryostatin 1 in the treatment of NHL. In light of preclinical data that demonstrate synergy between bryostatin 1 and several cytotoxic agents and cytokines, clinical studies to investigate bryostatin 1 in combination are warranted. We also present data to demonstrate that central venous lines may be used in future studies to avoid phlebitis. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>bryostatin 1</kwd><kwd>non-Hodgkin's lymphoma</kwd><kwd>protein kinase C inhibitors</kwd></kwd-group></article-meta></front></article>


